University of Toronto
utoronto.caTotal trials
402
Active
56
Phase 3
21
Total enrollment
711,466
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Intrathecal Morphine | — | — | — | — | — | 1 | |
| No Intrathecal Morphine | — | — | — | — | — | 1 | |
| Efavirenz 600mg | — | — | — | — | — | 1 |
Next readouts
- 2027-07-01
- 2027-11-15
Top conditions
- Obesity37
- Diabetes29
- Cardiovascular Diseases25
- Healthy20
- Hypertension19
- Metabolic Syndrome15
- Cardiovascular Disease12
- Type 2 Diabetes12
Frequently asked questions about University of Toronto
- How many clinical trials does University of Toronto have on ClinicalTrials.gov?
- University of Toronto is listed as the lead sponsor on 402 clinical trials in ClinicalTrials.gov, 56 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Toronto's trials are in Phase 3?
- 21 of University of Toronto's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does University of Toronto focus on?
- University of Toronto's most-studied conditions on ClinicalTrials.gov are Obesity, Diabetes, Cardiovascular Diseases, Healthy, Hypertension.
- When are University of Toronto's next clinical trial readouts?
- University of Toronto has 2 upcoming primary-completion readouts tracked here; the soonest is “Post-Operative Urinary Retention on Revision Knee Arthroplasty: the Role of Intrathecal Morphine”, expected around 2027-07-01.